Vorasidenib is primarily used in the treatment of cancers, particularly those associated with mutations in the IDH1 and IDH2 genes. These mutations are commonly found in certain types of gliomas and acute myeloid leukemia (AML). By inhibiting the mutated IDH enzymes, Vorasidenib helps to reduce the production of the oncometabolite 2-hydroxyglutarate (2-HG), which is known to drive tumor growth. This targeted approach allows for more precise treatment with potentially fewer side effects compared to traditional chemotherapy. Clinical trials have shown promising results in slowing tumor progression and improving patient outcomes, making it a valuable option in the management of IDH-mutant cancers.